io io: Re DNDN
Urche wrote:
"I think DNDN is a good bet as an investment, but I have scientific doubts about the long-term prospects for Provenge."
io io wrote:
"That seems to be a contradiction. Somewhere I read that 30%-40% of men aged 70 show evidence of PC. Can't see how you like DNDN while doubting "long-term prospects for Provenge"."
I don't want to belabor my reservations about Dendreon, which are being misconstrued as me being negative about the company. It's my second biggest holding, and I am confident it will be approved and be a landmark treatment. My reservations are about whether 5 years from now it will be the only or the best prostate cancer vaccine on the market.
I think of Provenge as analagous to Mevacor a decade or so ago when it was a landmark blockbuster in what became a successful class of even better drugs.
I hope that helps. I'm sorry for the confusion I have caused and I am ready to move on.
Urche
Market Data 
Markets 
AI
